Rosalind Advisors Inc. Reduces Position in InspireMD, Inc. (NYSE:NSPR)

Rosalind Advisors Inc. cut its stake in InspireMD, Inc. (NYSE:NSPR) by 0.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,495,783 shares of the company’s stock after selling 18,263 shares during the quarter. InspireMD accounts for about 3.3% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 13th largest holding. Rosalind Advisors Inc. owned 0.10% of InspireMD worth $6,564,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in NSPR. Essex Investment Management Co. LLC bought a new stake in shares of InspireMD during the 4th quarter valued at $191,000. Affiance Financial LLC boosted its stake in shares of InspireMD by 2.9% in the fourth quarter. Affiance Financial LLC now owns 189,122 shares of the company’s stock worth $497,000 after acquiring an additional 5,376 shares during the period. Parkman Healthcare Partners LLC bought a new stake in InspireMD during the 3rd quarter valued at approximately $279,000. Finally, Legato Capital Management LLC bought a new stake in shares of InspireMD during the fourth quarter valued at approximately $47,000. Institutional investors own 44.78% of the company’s stock.

InspireMD Trading Down 0.4 %

NYSE NSPR opened at $2.74 on Friday. The stock has a market cap of $81.35 million, a PE ratio of -3.65 and a beta of 0.88. The company’s 50-day moving average price is $2.86 and its 200-day moving average price is $2.76. InspireMD, Inc. has a 12 month low of $1.81 and a 12 month high of $3.80.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. StockNews.com started coverage on InspireMD in a report on Tuesday. They issued a “sell” rating on the stock. Lake Street Capital started coverage on shares of InspireMD in a research note on Wednesday, December 11th. They set a “buy” rating and a $5.00 price objective for the company.

InspireMD Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.